Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3000202 in Adult Patients With Selected Type 1 Interferonopathies
NCT06878365Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label, single-arm trial of BI 3000202 in type 1 interferonopathy, sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events related to study drug at 72 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
BI 3000202
03
Conditions
type 1 interferonopathy
Beyond the preview
Go deeper on NCT06878365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878365.